ResMed (RMD) Up 4% Since Last Earnings Report: Can It Continue?

Company Overview - ResMed (RMD) shares have increased by approximately 4% over the past month, underperforming the S&P 500 index [1] - The stock currently holds a Zacks Rank of 3 (Hold), indicating an expectation of an in-line return in the upcoming months [4] Earnings Estimates - Estimates for ResMed have trended upward over the past month, suggesting positive sentiment among analysts [2][4] - The stock has an aggregate VGM Score of C, with a Growth Score of B and a Momentum Score of D, indicating mixed performance across different investment strategies [3] Industry Comparison - ResMed is part of the Zacks Medical - Products industry, where another player, Neogen (NEOG), has seen a 19% increase in its stock price over the past month [5] - Neogen reported revenues of $220.98 million for the last quarter, reflecting a year-over-year decline of 3.4%, with an EPS of $0.10 compared to $0.12 a year ago [5] - Neogen's earnings estimates for the current quarter remain unchanged at $0.10 per share, but the Zacks Consensus Estimate has decreased by 23.8% over the last 30 days, resulting in a Zacks Rank of 4 (Sell) for Neogen [6]